Brown S G, McHugh G, Shapleski J, Wotherspoon P A, Taylor B J, Gillett W R
Department of Paediatrics and Child Health, University of Otago Medical School, Dunedin.
N Z Med J. 1989 Jan 25;102(860):3-5.
Haemorrhagic disease of the newborn is now a rare life threatening disease due to the widespread use of effective prophylaxis with vitamin K at birth. In recent years the continued need for routine prophylaxis has been questioned and alternative strategies proposed. We have reviewed the literature and using techniques of decision analysis, we reaffirm the need for continued prophylaxis. The cost for each life saved by an oral programme is $4500 and $11,000 for intramuscular prophylaxis. The cost to the state of no prophylactic programme is $6.40 per child born and $0.81 for an oral prophylactic programme. It is recommended that the oral route of vitamin K prophylaxis be adopted as it is equally efficacious with the intramuscular route, but cheaper, more consumer acceptable, and has a lower risk of iatrogenic disease.
由于目前在出生时广泛使用有效的维生素K预防措施,新生儿出血性疾病现在已成为一种罕见的危及生命的疾病。近年来,对常规预防措施的持续需求受到质疑,并提出了替代策略。我们回顾了文献,并使用决策分析技术,重申了持续预防的必要性。口服方案挽救每一条生命的成本为4500美元,肌肉注射预防方案为11000美元。不采取预防方案给国家带来的成本是每个新生儿6.40美元,口服预防方案则为0.81美元。建议采用口服维生素K预防途径,因为它与肌肉注射途径同样有效,但更便宜,更容易被消费者接受,且医源性疾病风险更低。